Platform 02 · Engineering cells that do what drugs cannot.
Cell & Gene-Edited Therapies
We engineer hypoimmune, off-the-shelf cell therapies using CRISPR-based gene editing. Our pipeline spans vascular progenitors, insulin-secreting beta cells, and CAR-T/NK platforms.
Overview
Our cell and gene therapy programs are built on a hypoimmune iPSC backbone — enabling allogeneic, off-the-shelf therapies that evade immune rejection without requiring life-long immunosuppression. CRISPR editing is applied at the iPSC stage, ensuring uniform genetic modification across differentiated progeny.
Therapeutic programs span critical limb ischemia (vascular progenitors), Type 1 Diabetes (insulin-secreting beta cells), heart failure (cardiomyocytes and vascular progenitors), and immuno-oncology (CAR-NK and CAR-T). All programs include IND-enabling CMC development at our cGMP facility.
Pipeline Programs
Critical Limb Ischemia
Hypoimmune iPSC-Endothelial + Vascular Progenitors
Type 1 Diabetes
Hypoimmune iPSC-β cells (insulin-secreting)
Cardiomyopathy
iPSC-Cardiomyocytes + Vascular progenitors
Immuno-Oncology
iPSC-CAR-NK / CAR-T cells